EU, FDA to share inspections data; EU signs off on Optimer, Astellas, diarrhea drug DIFICLIR;

  @FiercePharma: NHS data on prescriptions to be opened up to public under open data initiative. Story | Follow@FiercePharma

> Starting in January 2012, the European Medicines Agency and the U.S. FDA will begin to share their inspections data of manufacturing sites in each other's territories. Story

> Optimer Pharmaceuticals ($OPTR) and Astellas Pharma have gained marketing approval in Europe for DIFICLIR (fidaxomicin) tablets to treat adults with Clostridium difficile-associated diarrhea. Optimer release

> Takeda will begin Canadian marketing of AMAG Pharmaceuticals' ($AMAG) Feraheme, a new intravenous treatment for iron deficiency anemia in patients with chronic kidney disease, following the drug's Dec. 8 regulatory approval. Release

> Mylan ($MYL) has appointed John Thievon, former president and CEO of MiddleBrook Pharmaceuticals, as president of Dey Pharma, the company's fully integrated specialty pharmaceutical business. Mylan release

>The board of directors at Eli Lilly ($LLY) have elected Katherine Baicker as a new member. The health economics professor at the Harvard School of Public Health will serve on Lilly's public policy and compliance committee. Lilly release

Biotech News 

@FierceBiotech: Interesting piece from @eyeonfda on social media guidelines and clinical trials. Article | Follow @FierceBiotech

@JohnCFierce: Abbott bets $400M on Reata preclinical-in which CEO Huff laughs, tells me "no comment" on Abbott buyout bid. | Follow @JohnCFierce

@RyanMFierce: Say lots about FDA, but France's drug regulatory system looks like a mess in comparison. Article on Mediator scandal. | Follow @RyanMFierce

@MaureenFierce: Writing for New Scientist, the CEO of the UK's Science Media Center proposes 5 ways to fix science journalism. Article | Follow @MaureenFierce

> Gene therapy study offers proof of potential breakthrough on hemophilia. Item

> Pharmacyclics impresses (again) with improved leukemia data on blockbuster hopeful. Report

> Onyx shares slide after FDA forces investors to wait on standard carfilzomib review. News

Biotech IT News

> Pharma hacker gets jail sentence in NJ. Story

> Supercomputer software aids UK cancer researchers. Report

> IBM taps 'Watson-type' tech for drug research tool. Item

> Uncle Sam to award $20M for work on genomic data informatics. Report

> U. Cal professor recruits computer whizzes for war on cancer. Article

> U.K. injecting £75M into bioinformatics 'nerve center' for Europe. News

Medical Device News

> Bluegrass announces patient enrollment in catheter trial. News

> Boston Sci introduces Charger catheter. Report

> Tissue Regenix to raise $39M, eyes job creation. Article

> Symmetry to buy instruments biz of J&J unit for $165M. Story

And Finally... Bayer, the maker of Yaz, wants the Pennsylvania Supreme Court to take action against Philadelphia's common pleas court, which it says is actively encouraging out-of-state lawsuits over the drug. News

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.